療效碾壓阿斯利康(AZN.US)Imfinzi！Summit(SMMT.US)依沃西單抗III期試驗數據積極，股價應聲大漲

智通財經

08/26

【療效碾壓阿斯利康(AZN.US)Imfinzi！Summit(SMMT.US)依沃西單抗III期試驗數據積極，股價應聲大漲】智通財經APP獲悉，周三美股盤前，Summit Therapeutics(SMMT.US)股價一度大漲逾16%，此前該公司公布了後期試驗的積極數據。結果顯示，其核心候選藥物依沃西單抗(ivonescimab，由合作伙伴康方生物(09926.HK)授權引進)在療效上超越了阿斯利康(AZN.US)旗下的癌症藥物Imfinzi(通用名：度伐利尤單抗)。

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2662671167"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2662671167\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2662671167?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-08-26 20:32","share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","id":"2662671167","market":"us","top_or_hot":-1,"title":"療效碾壓阿斯利康(AZN.US)Imfinzi！Summit(SMMT.US)依沃西單抗III期試驗數據積極，股價應聲大漲","media":"智通財經","content":"<html><body><div>\n<div>\n<b>【療效碾壓阿斯利康(AZN.US)Imfinzi！Summit(SMMT.US)依沃西單抗III期試驗數據積極，股價應聲大漲】</b>智通財經APP獲悉，周三美股盤前，Summit \n\nTherapeutics(SMMT.US)股價一度大漲逾16%，此前該公司公布了後期試驗的積極數據。結果顯示，其核心候選藥物依沃西單抗(ivonescimab，由合作伙伴康方生物(09926.HK)授權引進)在療效上超越了阿斯利康(AZN.US)旗下的癌症藥物Imfinzi(通用名：度伐利尤單抗)。                </div>\n</div></body></html>","source":"live_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>療效碾壓阿斯利康(AZN.US)Imfinzi！Summit(SMMT.US)依沃西單抗III期試驗數據積極，股價應聲大漲</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n療效碾壓阿斯利康(AZN.US)Imfinzi！Summit(SMMT.US)依沃西單抗III期試驗數據積極，股價應聲大漲\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">智通財經</strong><span class=\"h-time small\">2026-08-26 20:32</span>\n</p>\n</h4>\n</header>\n<article>\n<html><body><div>\n<div>\n<b>【療效碾壓阿斯利康(AZN.US)Imfinzi！Summit(SMMT.US)依沃西單抗III期試驗數據積極，股價應聲大漲】</b>智通財經APP獲悉，周三美股盤前，Summit \n\nTherapeutics(SMMT.US)股價一度大漲逾16%，此前該公司公布了後期試驗的積極數據。結果顯示，其核心候選藥物依沃西單抗(ivonescimab，由合作伙伴康方生物(09926.HK)授權引進)在療效上超越了阿斯利康(AZN.US)旗下的癌症藥物Imfinzi(通用名：度伐利尤單抗)。                </div>\n</div></body></html>\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://www.zhitongcaijing.com/immediately.html?type=usstock\">智通財經</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2488822045.USD","symbol_name":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","start_time":0,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","article_id":"2662671167","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2662671167","pubTimestamp":1787747523,"columns":[],"sourceInfo":{"source_id":"live_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"【療效碾壓阿斯利康(AZN.US)Imfinzi！Summit(SMMT.US)依沃西單抗III期試驗數據積極，股價應聲大漲】智通財經APP獲悉，周三美股盤前，Summit \n\nTherapeutic","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","BK4134":"信息科技咨询与其它服务","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","LU0708994859.HKD":"TEMPLETON GLOBAL \"A\" (HKD) ACC","AZN":"阿斯利康","AZNH":"ASTRAZENECA PLC ADRhedged","IE00B3T34201.USD":"BNY MELLON GLOBAL EQUITY INCOME \"B\" (USD) INC","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","III":"信息服务","LU0029864427.USD":"TEMPLETON GLOBAL \"A\" (USD) INC","BK4588":"碎股","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU0128525929.USD":"TEMPLETON GLOBAL \"A\" (USD) ACC","BK4585":"ETF&股票定投概念","SMMT":"Summit Therapeutics PLC","BK4139":"生物科技","LU0058720904.USD":"联博国际健康护理基金A","LU2237443382.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA USD","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","LU2237443895.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) ACC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","LU0310800379.SGD":"FTIF - Templeton Global A Acc SGD","LU2237443465.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) INC","LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD","LU1267930573.SGD":"TEMPLETON GLOBAL \"AA\" (SGD) ACC A","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU1829250122.USD":"高盛欧洲核心股票组合Acc","LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","BK4007":"制药","BK4568":"美国抗疫概念","LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC"},"translate_title":"Efficacy Crushes AstraZeneca (AZN.US) Imfinzi! Summit (SMMT.US) Stock Surges in Response to Positive Evocizumab Phase III Trial Data","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AZN":1.5,"SMMT":1.5,"AZNH":0.6,"III":1.5},"content_text":"【療效碾壓阿斯利康(AZN.US)Imfinzi！Summit(SMMT.US)依沃西單抗III期試驗數據積極，股價應聲大漲】智通財經APP獲悉，周三美股盤前，Summit \n\nTherapeutics(SMMT.US)股價一度大漲逾16%，此前該公司公布了後期試驗的積極數據。結果顯示，其核心候選藥物依沃西單抗(ivonescimab，由合作伙伴康方生物(09926.HK)授權引進)在療效上超越了阿斯利康(AZN.US)旗下的癌症藥物Imfinzi(通用名：度伐利尤單抗)。","kind":"live","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}